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Abstract
Many children with Autism Spectrum Diseases (ASD) present with seizure activity, but the pathogenesis is not
understood. Recent evidence indicates that neuro-inflammation could contribute to seizures. We hypothesize that
brain mast cell activation due to allergic, environmental and/or stress triggers could lead to focal disruption of the
blood-brain barrier and neuro-inflammation, thus contributing to the development of seizures. Treating neuro-
inflammation may be useful when anti-seizure medications are ineffective.
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Background
Autism Spectrum Disorders (ASD) are pervasive neuro-
developmental disorders affecting almost 1/100 children
and are characterized by difficulties in social skills, con-
centration, language, learning and stereotypic behaviors
[1-3]. About 22-30% of children with ASD also develop
seizures with no specific underlying pathology, and no
obvious or classic EEG changes [1,4-7]. These rates of
seizures in ASD are about ten times higher than that in
the general population [8]. This high rate is not found
in other neurologic diseases such as schizophrenia [9].
Alterations in architecture of cortical neurons were
recently reported in autism [10] and may contribute to
seizures.
Epileptic symptoms in children with ASD were
recently considered to be related to immune-mediated
pathogenesis [11]. In fact, ASD are associated with some
immune dysfunction, such as elevated antibody levels
directed against the fetal brain [12-15] suggesting BBB
disruption. A recent paper from the Autism Phenome
Project reported that 42% of 3 year old children with
ASD and controls had plasma antibodies against
GABAergic cerebellar neuron proteins, but those control
children had high scores on the Child Behavior Check
list, suggesting that they may constitute a susceptible
subtype for ASD [16]. Moreover, IL-6 expression was
elevated in the brains of ASD patients [17], while
increased serum IL-6 was linked to the expression of an
autistic phenotype in mice [18,19].
There is new evidence that the environment contri-
butes significant to ASD pathogenesis [20]. Many ASD
patients suffer from food allergies [21]. Moreover, 25%
of ASD children have “allergic-like” symptomatology
[22], but often without positive skin or RAST tests, sug-
gesting mast cell activation by non-allergic triggers [23],
including mercury [24]. Many studies delineate the
importance of mast cells in both innate and acquired
immunity [25], as well as in inflammation [26]. Sub-
stances originating in the gut or the brain can trigger
mast cells to release mediators that could disrupt the
gut-blood barrier and blood-brain barrier (BBB), thus
contributing to the pathogenesis of autism [27]. Many
mediators, such as IL-6 [28], can be released from mast
cells “selectively” [29], making histological evaluation
impossible. More importantly, mast cells have been
implicated in the pathogenesis of seizures. One study
using a mouse model showed that the non-allergic mast
cell trigger compound 48/80 significantly increased the
rate of seizures in mice induced by electric shock, and
this effect was eliminated in mast cell-depleted mice
[30]. Moreover, the mast cell trigger neurotensin (NT)
[31] can facilitate N-Methyl-D-aspartate (NMDA)-
induced excitation of cortical neurons [32] and seizure
activity in rodents [33]. NT was increased in young chil-
dren with autism [34], and was proposed as a possible
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induce neurotoxicity [35].
Children with mastocytosis, a spectrum of diseases
that present with skin allergies and diarrhea, also com-
plain of learning disabilities, hyperactivity and difficulty
focusing ("brain fog”), reminiscent of ASD [36,37]. In
fact, children with mastocytosis have a 10-fold higher
prevalence of ASD (1/10 children) than that reported
for the general population (1/100 children) [38]. Inter-
estingly, mastocytosis patients also have high serum IL-6
levels [39,40] and develop seizures [41]. Also, a solitary
mastocytoma produced symptoms mimicing seizures
[42].
Hypothesis
Immune dysfunction and inflammation appear to alter
BBB integrity [43,44]. Recent evidence indicates that the
integrity of the BBB, especially leukocyte endothelial
adhesion may also be involved in the pathogenesis of
epilepsy [45], a phenomenon described as “immunology:
barrier to electrical storms” [46]. Mast cells were consid-
ered as the “immune gate to the brain” [47]. ASD
patients are prone to stress [48], and prenatal stress has
been linked to risk of autism [49]. The brain, especially
the hypothalamus, contains many mast cells critically
located around the BBB, and that stress activates brain
mast cells leading to BBB disruption [50]. Moreover,
corticotropin-releasing hormone (CRH), secreted under
stress, can activate mast cells [51] and is responsible for
mast cell-dependent BBB disruption [50,51]. The possi-
ble involvement of mast cells is further supported by
the ability of histamine-1 receptors to augment seizures
[52]. Brain mast cells also contribute to the pathogenesis
of migraine headaches [53] that increase the likelihood
of seizures [54]. Local activation of brain mast cells
could lead to focal disruption of the BBB, permitting
focal neuro-inflammation that could become an epilep-
t o g e n i cs i t e( F i g u r e1 ) .T h i sp r o c e s sc o u l dw o r s e nb y
activation of Fcgamma receptors (FcgRI) on neurons
that could contribute to brain cell death after injection
of the epileptogenic kainic acid [55]. Moreover, Fcepsi-
lon receptors (FcεRI), typically thought to be expressed
only by mast cells and basophils, were recently identified
on neurons [56] implying that allergic triggers may even
affect the neurons directly, once the BBB has been dis-
rupted to permit entry of immunoglobulins. A recent
publication reported that increased serum level of “high
mobility group box 1 protein (HMGB1) in young autis-
tic patients [57]. HMGB1 is released from neurons fol-
lowing neurotoxicity [58] and it was recently shown to
constitute a pro-seizure pathway through activation of
toll-like receptors (TLR-4) in mice [59]. We recently
showed that mast cell activation leads to mitochondrial
translocation to the cell surface [60], and secretion of
extracellular mtDNA [34]. We also showed that serum
of children with autism had increased levels of extracel-
lular mitochondrial DNA [61]. Damaged Associated
Molecular Patterns (DAMPs), which include mitochon-
drial DNA, were reported to be released from damaged
cells in trauma patients and activate TLR leading to
auto-inflammation [62]. Mitochondrial DNA was also
reported to be directly neurotoxic and alter behavior in
mice [63].
Anticonvulsant medications often are ineffective in
both ASD and mastocytosis patients with seizures [64].
It would, therefore, be important to use treatment
approaches directed to the core symptoms of ASD and/
or brain mast cell activation and inflammation [23]. Use
of select, natural, flavonoids, may be useful because of
their anti-oxidant and anti-inflammatory ability [65].
Luteolin is a flavone contained in chamomile and chry-
santhemum. Increasing evidence indicates that luteolin
has potent antioxidant, free radical scavenger, anti-
inflammatory and mast cell inhibitory activity [66]. In
addition, luteolin inhibits microglia IL-6 release [67,68],
as well as mimics the activity of brain-derived neuro-
trophic factor (BDNF) [69]. Luteolin also inhibits autis-
tic-like behavior in mice [70]. Luteolin also inhibits mast
cell-dependent stimulation of activated T cells [71], as
well as activated peripheral blood mononuclear cells
from patients with the brain inflammatory disease multi-
ple sclerosis [72]. Moreover, the structural flavone ana-
logue, quercetin, found in citrus pulp and peels, is also a
potent mast cell inhibitor [73] and has anti-seizure
activity [74], as does its natural glycoside rutin [75].
Figure 1 Mast cells are located perivascularly close to nerve
endings and regulate blood-brain barrier permeability. Upon
stimulation by allergic and non-immune triggers (e.g, CRH,
neurotensin, mercury, mitochondrial (mt) DNA), mast cells release
vasodilatory and inflammatory molecules (IL-6, mtDNA, TNF and
VEGF), some of which increase the expression of vascular
endothelial cell adhesion molecules (VCAMs) and permit exit of
circulating lymphocytes in the brain. Focal brain inflammation could
then contribute to or exacerbate seizures.
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neuroinflammation, including seizures in ASD children,
especially if administered in formulations that permit
sufficient oral absorption.
Implications
In conclusion, evidence reviewed above indicates a pos-
sible association between neuroinflammation, mast cell
activation and seizures, through secretion of pro-inflam-
matory mediators and regulation of the BBB permeabil-
ity. Mast cell function inhibitors, especially those
blocking the effect of NT, such as luteolin, may serve as
novel therapeutic agents for the treatment of autism and
related seizures.
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